Lexicon (LXRX) Q1 2026 Earnings Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LXRX
Wall Street analysts forecast LXRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.850
Low
2.10
Averages
4.03
High
6.00
Current: 1.850
Low
2.10
Averages
4.03
High
6.00
About LXRX
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lexicon (LXRX) Q1 2026 Earnings Transcript
See More
Lexicon Pharmaceuticals Reports Q1 2026 Revenue Surge and Reduced Losses
- Revenue Surge: Lexicon Pharmaceuticals reported Q1 2026 revenue of $21.1 million, a staggering 1574.6% increase year-over-year, exceeding market expectations by $11.32 million, indicating strong performance in product promotion and market demand.
- Significant Loss Reduction: The net loss for Q1 2026 was $1.0 million, or less than $0.01 per share, a substantial decrease from the $25.3 million loss, or $0.07 per share, in the same period of 2025, reflecting improved cost control and operational efficiency.
- Improved Cash Position: As of March 31, 2026, Lexicon had $199.7 million in cash, investments, and restricted cash, up from $125.2 million as of December 31, 2025, driven by $96.5 million in net proceeds from stock sales in February 2026.
- Strategic Investment Outlook: The strong financial performance in Q1 2026 provides robust funding support for Lexicon's ongoing R&D and market expansion, particularly with the SONATA-HCM project, which has surpassed 50% enrollment, laying a solid foundation for future growth.
See More
Lexicon Pharmaceuticals to Announce Q1 Earnings on May 7
- Earnings Announcement Schedule: Lexicon Pharmaceuticals is set to announce its Q1 2025 earnings on May 7 before market open, with consensus EPS estimated at -$0.04 and revenue forecasted at $9.78 million, a significant increase from $1.26 million in Q1 2025, indicating potential for revenue growth.
- Earnings Estimate Revisions: Over the past three months, Lexicon's EPS estimates have seen two upward revisions with no downward adjustments, reflecting analysts' growing confidence in the company's future profitability, while revenue estimates also experienced two upward revisions, indicating optimistic market demand for its products.
- SONATA-HCM Progress: Lexicon highlighted that enrollment for SONATA-HCM has surpassed 50% as part of its 2026 milestones, which not only indicates smooth progress in clinical trials but also lays a foundation for future revenue growth, thereby boosting investor confidence.
- Insider Trading Activity: Lexicon's stock price spiked following insider buying, demonstrating management's confidence in the company's future prospects, which may attract more investor interest in its stock performance.
See More
Novo Nordisk Advances Next-Gen Obesity Treatments with LX9851 Trial
- Clinical Trial Initiation: Novo Nordisk has announced the initiation of a Phase 1 study for LX9851, an oral non-incretin drug candidate from Lexicon Pharmaceuticals aimed at treating obesity and related metabolic disorders, marking a significant advancement in the company's obesity treatment efforts.
- Milestone Payment Triggered: The start of this trial triggers a second $10 million milestone payment to Lexicon under their licensing agreement signed in March 2025, granting Novo Nordisk exclusive global rights to develop and commercialize the drug, with Lexicon eligible for up to $1 billion in total milestone payments and royalties on future sales.
- Trial Scale and Timeline: The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants, expected to be completed by early 2027, demonstrating Novo Nordisk's commitment and strategic planning in advancing its drug pipeline.
- Market Reaction and Outlook: While NVO shares fell 1.5%, LXRX's stock rose about 1% in pre-market trading, reflecting market optimism regarding the new drug development and enhancing Novo Nordisk's competitive position in the obesity treatment market.
See More
Lexicon Pharmaceuticals and Novo Nordisk Launch Phase 1 Study for Oral Obesity Drug Candidate LX9851
Announcement of Phase 1 Study: Lexicon Pharmaceuticals and Novartis have announced the initiation of a Phase 1 study for the oral obesity drug candidate, LX9851.
Focus on Obesity Treatment: The study aims to evaluate the safety and efficacy of LX9851 as a potential treatment for obesity, highlighting the ongoing efforts in developing innovative therapies in this area.
See More
Lexicon Pharmaceuticals Q4 2025 Earnings Call Insights
- Core Program Progress: Lexicon Pharmaceuticals is advancing three late-stage programs in cardiometabolic disease and chronic pain, with significant progress in the development of sotagliflozin for hypertrophic cardiomyopathy, expected to submit an NDA in 2026, indicating a strategic focus on critical therapeutic areas.
- Financial Position Improvement: Total revenues for Q4 2025 were $5.5 million, with full-year revenues reaching $49.8 million, showing significant improvement from 2024, while net loss decreased from $33.8 million in 2024 to $15.5 million, reflecting successful cost control and operational efficiency.
- R&D Expense Optimization: R&D expenses for Q4 dropped to $11.3 million, halving compared to 2024, indicating Lexicon's more efficient resource allocation and continued focus on advancing core programs in the future.
- Future Outlook: Management expects operating expenses in 2026 to range between $100 million and $110 million, with R&D expenses projected at $63 million to $68 million, demonstrating confidence in future growth while emphasizing the smooth progress of the SONATA-HCM trial and plans for NDA resubmission for Zynquista.
See More
Lexicon (LXRX) Q1 2026 Earnings Transcript
See More
Lexicon Pharmaceuticals Reports Q1 2026 Revenue Surge and Reduced Losses
- Revenue Surge: Lexicon Pharmaceuticals reported Q1 2026 revenue of $21.1 million, a staggering 1574.6% increase year-over-year, exceeding market expectations by $11.32 million, indicating strong performance in product promotion and market demand.
- Significant Loss Reduction: The net loss for Q1 2026 was $1.0 million, or less than $0.01 per share, a substantial decrease from the $25.3 million loss, or $0.07 per share, in the same period of 2025, reflecting improved cost control and operational efficiency.
- Improved Cash Position: As of March 31, 2026, Lexicon had $199.7 million in cash, investments, and restricted cash, up from $125.2 million as of December 31, 2025, driven by $96.5 million in net proceeds from stock sales in February 2026.
- Strategic Investment Outlook: The strong financial performance in Q1 2026 provides robust funding support for Lexicon's ongoing R&D and market expansion, particularly with the SONATA-HCM project, which has surpassed 50% enrollment, laying a solid foundation for future growth.
See More
Lexicon Pharmaceuticals to Announce Q1 Earnings on May 7
- Earnings Announcement Schedule: Lexicon Pharmaceuticals is set to announce its Q1 2025 earnings on May 7 before market open, with consensus EPS estimated at -$0.04 and revenue forecasted at $9.78 million, a significant increase from $1.26 million in Q1 2025, indicating potential for revenue growth.
- Earnings Estimate Revisions: Over the past three months, Lexicon's EPS estimates have seen two upward revisions with no downward adjustments, reflecting analysts' growing confidence in the company's future profitability, while revenue estimates also experienced two upward revisions, indicating optimistic market demand for its products.
- SONATA-HCM Progress: Lexicon highlighted that enrollment for SONATA-HCM has surpassed 50% as part of its 2026 milestones, which not only indicates smooth progress in clinical trials but also lays a foundation for future revenue growth, thereby boosting investor confidence.
- Insider Trading Activity: Lexicon's stock price spiked following insider buying, demonstrating management's confidence in the company's future prospects, which may attract more investor interest in its stock performance.
See More
Novo Nordisk Advances Next-Gen Obesity Treatments with LX9851 Trial
- Clinical Trial Initiation: Novo Nordisk has announced the initiation of a Phase 1 study for LX9851, an oral non-incretin drug candidate from Lexicon Pharmaceuticals aimed at treating obesity and related metabolic disorders, marking a significant advancement in the company's obesity treatment efforts.
- Milestone Payment Triggered: The start of this trial triggers a second $10 million milestone payment to Lexicon under their licensing agreement signed in March 2025, granting Novo Nordisk exclusive global rights to develop and commercialize the drug, with Lexicon eligible for up to $1 billion in total milestone payments and royalties on future sales.
- Trial Scale and Timeline: The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants, expected to be completed by early 2027, demonstrating Novo Nordisk's commitment and strategic planning in advancing its drug pipeline.
- Market Reaction and Outlook: While NVO shares fell 1.5%, LXRX's stock rose about 1% in pre-market trading, reflecting market optimism regarding the new drug development and enhancing Novo Nordisk's competitive position in the obesity treatment market.
See More
Lexicon Pharmaceuticals and Novo Nordisk Launch Phase 1 Study for Oral Obesity Drug Candidate LX9851
Announcement of Phase 1 Study: Lexicon Pharmaceuticals and Novartis have announced the initiation of a Phase 1 study for the oral obesity drug candidate, LX9851.
Focus on Obesity Treatment: The study aims to evaluate the safety and efficacy of LX9851 as a potential treatment for obesity, highlighting the ongoing efforts in developing innovative therapies in this area.
See More
Lexicon Pharmaceuticals Q4 2025 Earnings Call Insights
- Core Program Progress: Lexicon Pharmaceuticals is advancing three late-stage programs in cardiometabolic disease and chronic pain, with significant progress in the development of sotagliflozin for hypertrophic cardiomyopathy, expected to submit an NDA in 2026, indicating a strategic focus on critical therapeutic areas.
- Financial Position Improvement: Total revenues for Q4 2025 were $5.5 million, with full-year revenues reaching $49.8 million, showing significant improvement from 2024, while net loss decreased from $33.8 million in 2024 to $15.5 million, reflecting successful cost control and operational efficiency.
- R&D Expense Optimization: R&D expenses for Q4 dropped to $11.3 million, halving compared to 2024, indicating Lexicon's more efficient resource allocation and continued focus on advancing core programs in the future.
- Future Outlook: Management expects operating expenses in 2026 to range between $100 million and $110 million, with R&D expenses projected at $63 million to $68 million, demonstrating confidence in future growth while emphasizing the smooth progress of the SONATA-HCM trial and plans for NDA resubmission for Zynquista.
See More
